文献速递脑血管病

脑微出血缺血性卒中患者他汀类药物治疗用于二级预防

Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds.
PubMed 文献 · Neurology · 2024-03-12

该研究汇总脑微出血国际协作网32项医院前瞻性研究的个体患者数据,纳入16373例缺血性卒中或短暂性脑缺血发作患者,其中4668例存在脑微出血。在脑微出血患者中,他汀使用与任何卒中风险降低相关(aHR 0.68),与缺血性卒中风险降低相关(aHR 0.65),与颅内出血风险无显著关联(aHR 0.73,95%CI 0.46-1.15)。

要点

  • 脑微出血患者中,他汀使用与任何卒中风险降低相关(aHR 0.68,95%CI 0.56-0.84)。
  • 脑微出血患者中,他汀使用与缺血性卒中风险降低相关(aHR 0.65,95%CI 0.51-0.82)。
  • 他汀使用与颅内出血风险无显著关联(aHR 0.73,95%CI 0.46-1.15)。

核心结论

  • 这些观察性数据提示,对伴有脑微出血的缺血性卒中或短暂性脑缺血发作患者,使用他汀进行二级卒中预防与任何卒中或缺血性卒中风险降低相关,且不增加颅内出血风险。
  • 本研究提供III级证据:对伴有脑微出血的缺血性卒中或短暂性脑缺血发作患者,他汀降低任何卒中或缺血性卒中风险而不增加颅内出血风险。

研究设计与样本

  • 本研究为脑微出血国际协作网个体患者数据的汇总分析,纳入32项医院前瞻性研究。
  • 纳入标准为:成年缺血性卒中或短暂性脑缺血发作患者,具备可用于脑微出血定量和分布的基线MRI,登记索引卒中后他汀使用情况,并收集随访≥3个月的卒中事件数据。
  • 共纳入16373例患者(平均年龄70.5±12.8岁;女性42.5%),其中10812例出院时接受他汀治疗,4668例有1个或以上脑微出血。
  • 中位随访时间为1.34年(四分位距:0.32-2.44)。

主要发现

  • 在脑微出血患者中,他汀使用者与非使用者相比,任何卒中发生率分别为53 vs 79/1000患者年,aHR 0.68(95%CI 0.56-0.84)。
  • 在脑微出血患者中,他汀使用者与非使用者相比,缺血性卒中发生率分别为39 vs 65/1000患者年,aHR 0.65(95%CI 0.51-0.82)。
  • 在脑微出血患者中,他汀使用者与非使用者相比,颅内出血发生率分别为11 vs 16/1000患者年,aHR 0.73(95%CI 0.46-1.15),无显著关联。
  • 考虑脑微出血的解剖分布和高负荷(≥5)时,aHR结果保持一致。

关键数值与推荐

  • 主要终点为复发性症状性卒中(缺血性卒中或颅内出血),次要终点包括单纯缺血性卒中或单纯颅内出血。
  • 采用Cox回归分析校正年龄、性别、高血压、心房颤动、既往卒中以及抗血小板或抗凝药物使用。
  • 本研究提供III级证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The association between statin use and the risk of intracranial hemorrhage (ICrH) following ischemic stroke (IS) or transient ischemic attack (TIA) in patients with cerebral microbleeds (CMBs) remains uncertain. This study investigated the risk of recurrent IS and ICrH in patients receiving statins based on the presence of CMBs. METHODS: We conducted a pooled analysis of individual patient data from the Microbleeds International Collaborative Network, comprising 32 hospital-based prospective studies fulfilling the following criteria: adult patients with IS or TIA, availability of appropriate baseline MRI for CMB quantification and distribution, registration of statin use after the index stroke, and collection of stroke event data during a follow-up period of ≥3 months. The primary endpoint was the occurrence of recurrent symptomatic stroke (IS or ICrH), while secondary endpoints included IS alone or ICrH alone. We calculated incidence rates and performed Cox regression analyses adjusting for age, sex, hypertension, atrial fibrillation, previous stroke, and use of antiplatelet or anticoagulant drugs to explore the association between statin use and stroke events during follow-up in patients with CMBs. RESULTS: In total, 16,373 patients were included (mean age 70.5 ± 12.8 years; 42.5% female). Among them, 10,812 received statins at discharge, and 4,668 had 1 or more CMBs. The median follow-up duration was 1.34 years (interquartile range: 0.32-2.44). In patients with CMBs, statin users were compared with nonusers. Compared with nonusers, statin therapy was associated with a reduced risk of any stroke (incidence rate [IR] 53 vs 79 per 1,000 patient-years, adjusted hazard ratio [aHR] 0.68 [95% CI 0.56-0.84]), a reduced risk of IS (IR 39 vs 65 per 1,000 patient-years, aHR 0.65 [95% CI 0.51-0.82]), and no association with the risk of ICrH (IR 11 vs 16 per 1,000 patient-years, aHR 0.73 [95% CI 0.46-1.15]). The results in aHR remained consistent when considering anatomical distribution and high burden (≥5) of CMBs. DISCUSSION: These observational data suggest that secondary stroke prevention with statins in patients with IS or TIA and CMBs is associated with a lower risk of any stroke or IS without an increased risk of ICrH. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with IS or TIA and CMBs, statins lower the risk of any stroke or IS without increasing the risk of ICrH.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Prats-Sanchez L, Camps-Renom P, Nash PS, et al. Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds. Neurology. 2024. PMID: 38471056. doi:10.1212/WNL.0000000000209173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。